Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary

Greenwich Lifesciences

12/08/2026 22:05

Greenwich Lifesciences Inc GLSI.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -30 cents.  The mean expectation of two analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -36 cents to -30 cents per share.
Reported revenue was zero​; analysts expected zero. 
Greenwich Lifesciences Inc's reported EPS for the quarter was a loss of 27 cents​.
The company reported a quarterly loss of $3.95 million.
Greenwich Lifesciences Inc shares had fallen by 33.7% this quarter and lost 26.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Greenwich Lifesciences Inc is $57.00, about 72.7% above its last closing price of $15.55
This summary was machine generated from LSEG data August 12 at 09:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.33
-0.27
Beat
Mar. 31 2026 
-0.33
-0.39
Missed
Dec. 31 2025 
-0.32
-0.58
Missed
Sep. 30 2025 
-0.29
-0.30
Missed